KeypointsSinonasal melanomas.Adjuvant radiotherapy.INTRODUCTIONSinonasal mucosal melanoma is a rare malignancy with a reported incidence rate of 0.05 per 100 000 in the United States. In the Netherlands, this disease accounts for 8% of all sinonasal malignancies. The prognosis is poor, with an estimated 5‐year overall survival (OS) of 21.8%‐40.1%. The aggressive behaviour of this tumour results in advanced disease at diagnosis and high rates of local (38%‐46.6%) and distant recurrence (34.6%‐66%).Due to the low incidence of this disease, the development of a standardised treatment protocol and prognostic models has been difficult. Surgical resection with clear margins has been the key mode of treatment with curative intent. Ideally, all unilateral mucosa should be removed, as this malignancy often presents with multifocal lesions that could easily be missed. However, given the complex anatomy of the sinonasal tract with close relation to vital structures, radical resection is often hard to achieve. In case of incomplete resection, post‐operative radiotherapy is advocated. No consensus has been reached regarding the use of adjuvant radiotherapy: while some studies reported better local control and sometimes even better OS, other studies did not find any difference. The same problem applies for prognostic factors for recurrence and survival: the predictors reported
Clinical Otolaryngology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera